Clinical Trials · NCT03624517

Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

Name: Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 4Octreotide

Phase: Phase 4
Recruitment status: Terminated
Sponsor: Medical University of South Carolina
Enrollment: 34
Start date: Sep 2018
Locations: 8 sites, United States
Primary endpoint: Esophageal Varices Rebleed Within 72-hours After Control of Initial Bleed

View Octreotide compound reference